Literature DB >> 19463588

Aortic valve replacement for patients with severe aortic stenosis: risk factors and their impact on 30-month mortality.

Edward L Hannan1, Zaza Samadashvili, Stephen J Lahey, Craig R Smith, Alfred T Culliford, Robert S D Higgins, Jeffrey P Gold, Robert H Jones.   

Abstract

BACKGROUND: Few studies have reported population-based outcomes for aortic valve replacement patients.
METHODS: Patients with severe aortic valve stenosis who underwent aortic valve replacement with or without concomitant coronary artery bypass graft surgery from January 1, 2003, to December 31, 2005, were included in the study. Statistical models were developed to identify significant risk factors for mortality, to compare survival for patients with and without selected risk factors, and to compare survival to an age- and sex-matched group from US life tables.
RESULTS: There was total of 6,369 patients in the study. The in-hospital and 30-day mortality rates were 3.97% for aortic valve replacement and 5.69% for aortic valve replacement with concomitant coronary artery bypass graft surgery. Significant risk factors for 30-month mortality included concomitant coronary artery bypass graft surgery, advancing age, lower body surface area, emergency status, low ejection fraction, congestive heart failure, previous heart surgery, and several comorbidities. The 64.3% of patients with isolated aortic valve replacement who had neither congestive heart failure, ejection fraction less than 0.40, acute myocardial infarction less than 24 hours, nor hemodynamic instability had a risk-adjusted survival of 89.9% compared with the 90.0% survival rate of the age- and sex-matched general population (p = 0.28).
CONCLUSIONS: For the large number of patients without high-risk conditions, the 30-month survival is essentially as high as that of an age- and sex-matched group of the US population.

Entities:  

Mesh:

Year:  2009        PMID: 19463588     DOI: 10.1016/j.athoracsur.2009.02.058

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Impact of New York Heart Association classification, advanced age and patient-prosthesis mismatch on outcomes in aortic valve replacement surgery.

Authors:  Alex Zapolanski; Andrew W C Mak; Giovanni Ferrari; Christopher Johnson; Richard E Shaw; Mariano E Brizzio; Jason S Sperling; Juan B Grau
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-04

2.  Aortic valve replacement in patients with a left ventricular ejection fraction ≤35% performed via a minimally invasive right thoracotomy.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; Angelo La Pietra; Maurice Mawad; Vicente Behrens; Esteban Escolar; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

3.  Preoperative diastolic function predicts the onset of left ventricular dysfunction following aortic valve replacement in high-risk patients with aortic stenosis.

Authors:  Marc Licker; Mustafa Cikirikcioglu; Cidgem Inan; Vanessa Cartier; Afksendyios Kalangos; Thomas Theologou; Tiziano Cassina; John Diaper
Journal:  Crit Care       Date:  2010-06-03       Impact factor: 9.097

Review 4.  Development of aortic valve implantation.

Authors:  Nawwar Al-Attar; Patrick Nataf
Journal:  Herz       Date:  2009-08       Impact factor: 1.443

5.  Management of aortic stenosis: a systematic review of clinical practice guidelines and recommendations.

Authors:  Mohammed Y Khanji; Fabrizio Ricci; Victor Galusko; Baskar Sekar; C Anwar A Chahal; Laura Ceriello; Sabina Gallina; Simon Kennon; Wael I Awad; Adrian Ionescu
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2021-07-21

6.  Beating aortic valve replacement surgery as an alternative to transcatheter aortic valve implantation in a patient with severe aortic stenosis and left ventricular dysfunction.

Authors:  Kenji Iino; Yoshitaka Yamamoto; Hideyasu Ueda; Hirofumi Takemura
Journal:  J Cardiothorac Surg       Date:  2018-12-27       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.